Summary Coronavirus disease 2019 (COVID-19) exhibits variable symptom severity ranging
from asymptomatic to life-threatening, yet the relationship between severity and the humoral …

Monoclonal antibodies with neutralizing activity against SARS-CoV-2 have demonstrated
clinical benefits in cases of mild-to-moderate SARS-CoV-2 infection, substantially reducing …

The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
Several vaccine approaches and repurposed drugs are currently under evaluation for safety …

Structural principles underlying the composition and synergistic mechanisms of protective
monoclonal antibody cocktails are poorly defined. Here, we exploited antibody cooperativity …

Summary Many SARS-CoV-2-infected individuals remain asymptomatic. Little is known
about the extent and quality of their antiviral humoral response. Here, we analyze antibody …

Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome
(SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social …

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

ABSTRACT VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs)
targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS …

Neutralizing antibodies (NAbs) are central players in the humoral immunity that defends the
body from SARS-CoV-2 infection by blocking viral entry into host cells and neutralizing their …